The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc announced plans to present new findings on responsive thalamic neuromodulation during a breakfast symposium at the ASSFN meeting.
The session, scheduled for Monday, June 1 at 7 AM, will feature discussions on 18-month Nautilus study results and updates on a feasibility study for Lennox-Gastaut Syndrome (LGS), with leading researchers Drs. Rolston, Richardson, and Morrell. Attendance is limited and advance reservation is required for the event.
NeuroPace previously invited ASSFN fellows to an exclusive networking dinner focused on neuromodulation practice growth after fellowship, with attendance limited to 30 seats, according to a recent announcement. The company also published a study in Green Journal revealing long-term benefits of its RNS System for drug-resistant epilepsy patients, as detailed in a previous report. These activities highlight NeuroPace’s ongoing engagement with the clinical neuromodulation community.